Stock Analiz

Design Therapeutics, Inc. DSGN

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$10.47Market cap $670M
Open the interactive analysis →

Design Therapeutics, Inc. (DSGN) is a healthcare company listed in the US with a market value of about $670M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -19%.

About Design Therapeutics

Design Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 3% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B3.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-8.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-19.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue$0$0———$226000
Net income-$70M-$50M-$67M-$63M-$36M-$8M
Free cash flow-$55M-$43M-$59M-$52M-$31M-$9M
EPS (diluted)$-1.22$-0.88$-1.19$-1.14$-0.77$-0.52
Net margin—————-3663.7%
ROIC-29.3%-20.2%-22.0%-16.1%-7.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 7 analysts is $21.57, 106% above the current price; targets range from $19.00 to $26.00; the consensus rating is “Strong buy”; expected EPS is $-1.34 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Design Therapeutics pay a dividend?

Not currently.

Is Design Therapeutics a good stock to buy?

We do not give buy or sell advice. Design Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.